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Abstract. 73 
Objectives: We used biomarker profiles to characterize differences between patients with acute 74 
heart failure with mid-range ejection fraction (HFmrEF) and compare them to patients with a 75 
reduced (HFrEF) and preserved (HFpEF) ejection fraction.  76 
Background: Limited data is available on biomarker profiles in acute HFmrEF. 77 
Methods: A panel of 37 biomarkers from different pathophysiological domains (e.g., myocardial 78 
stretch, inflammation, angiogenesis, oxidative stress, hematopoiesis) were measured at admission 79 
and after 24h in 843 AHF patients from the PROTECT trial. HFpEF was defined as LVEF 80 
≥50%(n=108), HFrEF as LVEF <40%(n=607) and HFmrEF as LVEF 40-49%(n=128).  81 
Results: Hemoglobin and BNP levels (300 pg/mL (HFpEF); 397 pg/mL (HFmrEF) 521 pg/mL 82 
(HFrEF, ptrend <0.001) showed an upward trend with decreasing LVEF. Network analysis showed 83 
that in HFrEF interactions between biomarkers were mostly related to cardiac stretch, whereas in 84 
HFpEF, biomarker interactions were mostly related to inflammation. In HFmrEF biomarker 85 
interactions were both related to inflammation and cardiac stretch. In HFpEF and HFmrEF (but not 86 
in HFrEF), remodeling markers at admission and changes in levels of inflammatory markers across 87 
the first 24 hours were predictive for all-cause mortality and rehospitalization at 60 days (Pinteraction 88 
<0.05). 89 
Conclusions: Biomarker profiles in patients with acute HFrEF were mainly related to cardiac 90 
stretch and in HFpEF related to inflammation. Patients with HFmrEF showed an intermediate 91 
biomarker profile with biomarker interactions between both cardiac stretch and inflammation 92 
markers.  93 
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 98 
 99 
Introduction. 100 
Heart failure with a midrange ejection fraction (HFmrEF) has recently been recognized as a new 101 
entity within the heart failure (HF) syndrome(1, 2). There is limited understanding of the 102 
differences in pathophysiological mechanisms behind HFmrEF, and how these relate to HF with a 103 
reduced (HFrEF) and with a preserved (HFpEF) ejection fraction. Previous attempts to understand 104 
potential differences in HFrEF and HFpEF have used biomarker-based approaches (3–7). In these 105 
conventional biomarker-based studies, baseline biomarker levels and the prognostic value of 106 
different biomarkers have been observed between HFrEF and HFpEF (5, 6). However, these 107 
approaches were restricted to a limited number of biomarkers measured at a single time point using 108 
conventional statistical methods with limited power to uncover underlying pathophysiological 109 
differences. Additionally, biomarker profiles of HFmrEF have not been investigated (8–10).   110 
Recently, novel approaches have been useful in increasing the understanding of the 111 
pathophysiology of chronic HF by uncovering biomarker associations, previously overlooked by 112 
conventional methods (10, 11). In the current study, we aimed to characterize biomarker profiles of 113 
patients with HFmrEF and compared these to biomarker profiles of HFrEF and HFpEF (1).  114 
  115 
Methods. 116 
Study design and population.  117 
This study was performed in a subcohort of the Patients Hospitalized with acute heart failure and 118 
Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion (PROTECT) 119 
trial. The results and methodology of PROTECT have been published previously (12–14). In short, 120 
the PROTECT trial was a multicenter, randomized, double blinded, placebo-controlled trial 121 
assessing the effect of the Selective A1 Adenosine Receptor Antagonist Rolofylline in 2033 patients 122 
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with a history of HF, who were admitted with AHF and mild-moderate renal dysfunction. Patients 123 
eligible for inclusion had NT-proBNP levels of >2000 pg/mL with dyspnea at rest or at mild 124 
exertion. Patients with severe renal dysfunction or potassium levels below 3.1 mmol/L were 125 
excluded (12). Overall results of this trial were neutral (14). Biomarker measurements were 126 
performed in 1266 patients. This study assessed a subcohort of 843 patients with available 127 
measurements of left ventricular ejection fraction (LVEF) and biomarkers at admission, which were 128 
similar in characteristics to the original study population (supplementary table 1). Subsequent 129 
biomarker samples after 24h were available in 790 patients. 130 
 131 
Study measurements and laboratory tests.  132 
Blood sampling was performed at admission before the administration of the study drug and after 133 
24h. Echocardiographic assessment of LVEF was performed at admission or within 6 months prior 134 
to admission. A total of 435 (52%) of the echocardiograms were performed at or around admission. 135 
HFpEF was defined as having an LVEF ≥50%, while HFrEF was defined as an LVEF <40%. 136 
Patients with a LVEF between 40-49% were considered to have HFmrEF (HF with mid-range 137 
ejection fraction) (1). A panel of 27 novel and established biomarkers were measured by Alere Inc., 138 
San Diego, CA, USA in all available samples. Table 1 summarizes the biomarkers according to 139 
pathophysiological domain. A literature summary for each biomarker was previously 140 
performed(11). The classification of biomarkers is based on current literature, however the 141 
pathophysiological mechanism behind each biomarker should be judged for each biomarker 142 
individually. Galectin-3, Myeloperoxidase (MPO) and Neutrophil gelatinase-associated lipocalin 143 
(NGAL) were measured using sandwich enzyme-linked immunosorbent assays (ELISA) on a 144 
microtiter plate; Angiogenin and C-reactive protein (CRP) were measured using competitive 145 
ELISAs on a Luminex® platform; D-dimer, endothelial cell-selective adhesion molecule (ESAM), 146 
growth differentiation factor 15 (GDF-15), lymphotoxin beta receptor (LTBR), Mesothelin, 147 
Neuropilin, N-terminal pro C-type natriuretic peptide (NTpro-CNP), Osteopontin, procalcitonin 148 
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(PCT), Pentraxin-3, Periostin, PIGR, pro-adrenomedullin (proADM), Prosaposin B (PSAP-B), 149 
RAGE, soluble ST2, Syndecan-1, tumor necrosis factor alpha receptor 1 (TNF-R1a), TROY, 150 
vascular endothelial growth receptor 1(VEGFR1) and WAP Four-Disulphide Core Domain Protein 151 
HE4 (WAP4C) were measured using sandwich ELISAs on a Luminex® platform. A panel of four 152 
biomarkers – Endothelin-1 (ET-1), Interleukin-6 (IL-6), Kidney Injury Molecule 1 (KIM-1) and 153 
cardiac specific Troponin I (cTnI) was measured in frozen plasma samples collected at baseline 154 
using high sensitive single molecule counting (SMC™) technology (RUO, Erenna® Immunoassay 155 
System, Singulex Inc., Alameda, CA, USA). Research assays of MR-proADM, galectin-3, and ST2 156 
were developed by Alere, and have not been standardized to the commercialized assays used in 157 
research or in clinical use. The extent to which each Alere assay correlates with the commercial 158 
assay is not fully characterized. Assay information included inter-assay coefficient of variation are 159 
provided in supplementary table 2. Estimated glomerular filtration rate (eGFR) was based on the 160 
simplified Modification of Diet in Renal Disease (MDRD) (15).  161 
 162 
Outcome. 163 
The primary outcome of this study was all-cause mortality and/or rehospitalization at 60 days’ post 164 
admission. This outcome was chosen because of the relatively large event rate in comparison to the 165 
other outcomes in the PROTECT trial. A blinded clinical events committee adjudicated the 166 
outcome.  167 
 168 
Statistical analysis 169 
Continuous variables are presented as means ± standard deviations or medians with interquartile 170 
ranges. Categorical variables are presented as numbers or percentages. Intergroup differences were 171 
analyzed using Students’ t-test, Mann-Whitney-U test, Kruskal-Wallis test, Analysis of Variance 172 
(ANOVA) or chi2-test where appropriate.  173 
 To correct for multiple comparisons, principal component (PC) analysis was performed with 174 
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HFrEF and HFpEF as categorical variables, using an established method described elsewhere (16). 175 
A total of 27 PCs cumulatively explained >95% of the variation observed in the dataset when 176 
comparing HFrEF and HFpEF (supplementary figures 1 & 2). The corrected significance level for 177 
multiple testing was thus set at P <0.05/27. Following this, a spearman’s rank correlation coefficient 178 
was calculated for each possible biomarker pair in the HFrEF cohort of patients and the procedure 179 
was repeated for HFpEF and HFmrEF. This resulted in three sets of R-values with associated p-180 
values for HFrEF, HFmrEF and HFpEF. To adjust for multiple testing, only those correlations 181 
passing the adjusted p-value cut-off calculated from the PC-Analysis (PCA) were deemed 182 
statistically significant and subsequently retained.  These significant correlation coefficients for 183 
HFrEF, HFmrEF and HFpEF were then graphically displayed as heatmaps with associated disease 184 
domains for all biomarkers. Network analysis was performed to analyze associations between 185 
biomarkers in HFrEF, HFmrEF and HFpEF.  Subsequently, all significant associations found within 186 
HFrEF, HFmrEF and HFpEF were separately depicted as circular networks, consisting of nodes 187 
(biomarkers) and edges (associations). In each network, the size and color of the nodes reflect the 188 
clustering coefficient of each biomarker, while the thickness of the lines (edges) represent the 189 
strength of the inter-biomarker associations (determined by spearman's rank coefficient R values).  190 
 To study the possible differential relationship with outcome of biomarkers, a univariable 191 
interaction test was performed between LVEF and the biomarker levels at admission or a change in 192 
biomarker levels between admission and the first 24h. Following this, a multivariable interaction 193 
test was performed correcting for a risk engine containing 8 variables, specifically designed for this 194 
cohort (17). These variables include age, previous HF hospitalizations, peripheral edema, systolic 195 
blood pressure, serum sodium, urea, creatinine and albumin levels at admission. Univariable and 196 
multivariable associations of biomarkers with outcome were tested using Cox regression analysis; 197 
due to the exploratory nature of these analyses, a p-value of <0.05 was deemed statistically 198 
significant for the interaction test. 199 
All tests were performed two-sided and a p-value of <0.05 was considered statistically 200 
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significant. All statistical analyses were performed using STATA version 11.0 (StataCorp LP, 201 
College station, Texas, USA) and R version 3.2.4. 202 
 203 
 204 
Results. 205 
Baseline characteristics 206 
Baseline characteristics are presented in table 2. Patients with HFmrEF were older than HFrEF 207 
patients, but younger than HFpEF (71 vs. 68 and 74 years respectively, P-value for trend <0.001). 208 
With increasing LVEF, the percentage of female patients, BMI, systolic blood pressure and 209 
diastolic blood pressure was higher (P-trend <0.05). We observed less mitral regurgitation, less 210 
previous HF hospitalizations during the past year, and less ischemic heart disease and myocardial 211 
infarction with increasing LVEF (P-trend all <0.001). Median time since the previous HF 212 
hospitalization was 52 days and did not differ between HFrEF; HFmrEF and HFpEF (p = 0.776). In 213 
contrast, a history of hypertension (P-trend <0.001) and atrial fibrillation (P-trend 0.014) was found 214 
more often with increasing LVEF. A direct comparison between HFmrEF - HFrEF and HFmrEF - 215 
HFpEF confirms these results (supplementary tables 3 & 4).  216 
 217 
Biomarker levels. 218 
Biomarker levels at admission are presented in table 3.  With increasing LVEF, we found 219 
increasing levels of CRP, NGAL, KIM-1 and platelet count and decreasing levels of GDF-15, BNP, 220 
Troponin-I, RBC, hemoglobin and endothelin-1. After correction for multiple comparisons, the up- 221 
or down sloping trend remained significant for BNP, KIM-1, RBC and hemoglobin. When 222 
examining a change of biomarkers from admission to 24-hours, troponin-I increased more in 223 
patients with HFrEF than in patients with HFmrEF and HFpEF, however significance was lost after 224 
correction for multiple comparisons (supplementary table 5). No significant interaction was found 225 
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between the study drug and LVEF for biomarkers that significantly differed between HFrEF; 226 
HFmrEF and HFpEF, also no significant interactions were observed between timing of 227 
echocardiography and LVEF for biomarker levels (p-interaction all >0.1).  228 
 229 
 230 
Network analysis. 231 
Heatmaps of biomarker associations are available in supplementary figures 3-5. The results 232 
of Network analysis are shown in figure 1-3. At admission, network analysis in HFrEF showed 233 
Troponin-I, BNP and PSAP-B to be a hub. A biomarker which is a hub has a high clustering 234 
coefficient. A high clustering coefficient suggests a certain centrality of the biomarker within the 235 
network, where a large number of the biomarker interactions are mediated through the hub. In 236 
HFpEF, angiogenin, hemoglobin, galectin-3 as well as d-dimer were hubs. Compared to HFrEF, 237 
BNP is only moderately associated with other biomarkers in HFpEF at admission. Interestingly, in 238 
HFmrEF, hemoglobin, RBC, endothelin-1 as well as BNP and galectin-3 were clear hubs at 239 
admission. After 24hrs interactions of biomarkers in patients with HFrEF were mainly associated 240 
with BNP and endothelin-1. In comparison, after 24hrs, biomarkers in HFpEF were mainly 241 
associated with inflammation markers pentraxin-3 and RAGE, as well as with remodeling marker 242 
osteopontin, angiogenesis marker angiogenin, hematopoiesis markers hemoglobin and red blood 243 
cell count as well as renal function marker NGAL. Interestingly, BNP remains a small hub in 244 
HFpEF. In HFmrEF, after 24hrs, the association between BNP and other biomarkers became very 245 
limited. Furthermore, remodeling marker galectin-3 and inflammation marker RAGE were 246 
continuous hubs at admission through the first 24hrs.  247 
 248 
Biomarker levels and outcome. 249 
Associations of biomarkers levels at admission with outcome are shown in supplementary tables 6 250 
Remodeling markers syndecan-1 (p = 0.047) and galectin-3 (p = 0.024) showed a significant 251 
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interaction for the primary outcome. Here, syndecan-1 showed a significant association with 252 
outcome in HFmrEF and HFpEF, but not in HFrEF. Also, galectin-3 showed significant predictive 253 
value in HFpEF, but not in HFmrEF and HFrEF.  254 
 The associations with outcome of a change of biomarker levels within the first 24 hours is 255 
show in supplementary table 7. A significant multivariable interaction was found for the 256 
inflammation biomarkers pentraxin-3 (p = 0.025), RAGE (p = 0.037), TNF-R1a (p = 0.004), 257 
oxidative stress marker MPO (p = 0.017) and the endothelial function marker proADM (p = 0.016) 258 
as well as arteriosclerosis marker LTBR (p = 0.009). Following multivariable correction, pentraxin-259 
3 was more predictive in HFmrEF and HFpEF, but not in HFrEF. A change in levels of TNF-R1a, 260 
MPO and LTBR were related to outcome in HFpEF, but not in HFrEF and HFmrEF. Interestingly, a 261 
change of endothelial function marker pro-ADM only had predictive power in HFmrEF, but not in 262 
HFrEF and HFpEF (supplementary table 7).  263 
 264 
Discussion. 265 
This study demonstrates differential biomarker profiles between AHF patients with HFrEF, 266 
HFmrEF and HFpEF. Network analysis showed that in HFmrEF, interaction between biomarkers 267 
were associated with BNP, galectin-3 and endothelin-1. In contrast, interactions between 268 
biomarkers in HFrEF were mostly associated with BNP, KIM-1 and Troponin-I, while in HFpEF, 269 
biomarkers associated with inflammation and endothelial function played a central role. Both in 270 
terms of clinical characteristics and biomarker profiles, patients with HFmrEF were in between 271 
HFpEF and HFrEF.  Biomarkers profiles of HFmrEF, HFpEF and HFrEF remained relatively stable 272 
throughout the first 24h post hospital admission. With regard to outcome, markers of inflammation 273 
showed independent predictive value in HFmrEF and HFpEF, but not in HFrEF. Levels of 274 
remodeling markers syndecan-1 and galectin-3 showed predictive value in HFmrEF and HFpEF, 275 
but not in HFrEF. Of note, pro-ADM showed predictive value in HFmrEF, but not in HFrEF and 276 
HFpEF.  277 
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Biomarker levels of patients with HFmrEF were between HFrEF and HFpEF. HFrEF 278 
patients had higher levels of biomarkers related to cardiac stretch and hematopoiesis. Network 279 
analysis showed an inter-association between biomarkers related to inflammation and cardiac 280 
stretch in HFmrEF. In HFpEF, associations related to inflammation and BNP only played a very 281 
marginal role in associations between biomarkers. In HFrEF, BNP had a more prominent role in 282 
network analyses both at admission and after 24h. In HFmrEF, a mix of associations between 283 
cardiac stretch and inflammation was observed. In an earlier publication in a chronic HF setting, 284 
associations between inflammation markers were seen in HFpEF, while in HFrEF associations were 285 
found between cardiac stretch markers (10). Indeed, also in this study, network analysis revealed 286 
patterns, which were previously unknown in HFrEF and HFpEF. Biomarkers in the intermediate 287 
group were more related to HFpEF than to HFrEF in this sub-analysis of the TIME-CHF trial (10). 288 
This could potentially be explained by the difference in inclusion criteria, where for the PROTECT 289 
trial a minimum NT-proBNP above >2000 pg/mL had to be present at admission, while this was not 290 
required for the TIME-CHF trial (18). HFpEF patients are known to have lower BNP and NT-291 
proBNP levels compared to HFrEF, which could explain why the proportion of HFpEF patients in 292 
the PROTECT trial is lower (7).    293 
Remodeling marker syndecan-1 had predictive value in HFmrEF and HFpEF, but not in 294 
HFrEF. This was previously shown in a stable HF setting, where syndecan-1 had predictive value in 295 
HFpEF but not in HFrEF (5). In an earlier publication about syndecan-1, HFpEF was defined at 296 
LVEF>40%, suggesting that syndecan-1 also in a chronic setting provides predictive value in both 297 
HFmrEF and HFpEF. Galectin-3 only showed predictive value in HFpEF, but not in HFrEF and 298 
HFmrEF, in line with an earlier publication (19). Furthermore, a change in levels of inflammation 299 
markers pentraxin-3 and TNF-R1a were predictive in HFpEF, but not in HFrEF. The role of 300 
pentraxin-3 in HFpEF is readily known (20). In earlier reports, circulating TNF-R1a levels 301 
predicted incident cardiovascular disease, including HF (21). In a particular study addressing 302 
chronic HF, TNF-R1 was the strongest predictor of long-term mortality (22). Higher levels of TNF-303 
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R were previously reported in HFpEF patients (23).  Levels of MPO were previously correlated 304 
with NYHA stage and diastolic HF and is considered to be both a marker of inflammation and 305 
oxidative stress (24, 25). A change in levels of MPO was predictive in HFpEF, but not in HFmrEF 306 
and HFrEF. LTBR is a member of the tumor necrosis factor family (26, 27). Activation of LTBR 307 
results in lymphocyte recruitment and is associated with inflammatory responses in atherosclerosis 308 
(26, 28). No data is available on predictive value in HF; and this is the first study reporting the 309 
differential involvement in predicting outcome in AHF patients with HFrEF, HFmrEF and HFpEF. 310 
Of note, TNF-R1a and LTBR are members of the TNF family of cytokines, suggesting a possible 311 
involvement of this family of proteins. Members of the TNF-alpha super family are involved in 312 
nitric oxide handling, which is considered a key mechanism in HFpEF. Whether other members of 313 
the TNF-alpha superfamily have a significant role in the pathophysiology of HFpEF needs to be 314 
explored further.  315 
The clinical implications of this study are fourfold. First of all, both the clinical and 316 
biomarker profiles of patients with HFmrEF were in between of HFrEF and HFpEF. This suggests 317 
that HFmrEF is a mix of patients similar to both HFrEF and HFpEF. There could be a considerable 318 
number of patients among HFmrEF who are closer to HFrEF and might benefit from existing HF-319 
guideline directed therapy. Previously, large HF trials had either excluded or embedded HFmrEF 320 
within the HFpEF group (1). Future studies should distinguish which HFmrEF patients are closer to 321 
HFrEF and which are closer to HFpEF. Biomarkers could aid in recognizing patients with HFmrEF 322 
that are closer to HFrEF. These patients are likely characterized by high NT-proBNP and high 323 
cardiac damage markers, while having lower levels of inflammation markers compared to HFpEF 324 
patients. These patients could subsequently benefit from guideline-directed therapy and can 325 
possibly be included in future HF trials with HFrEF patients. Secondly, patients with HFpEF have a 326 
distinct biomarker profile from those with HFrEF, with patients with HFpEF having lower levels of 327 
cardiac stretch markers. Also, inflammation related biomarkers had more predictive value in HFpEF 328 
and HFmrEF than in HFrEF. Thirdly, overall biomarker profiles stay relatively stable in both 329 
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HFrEF, HFmrEF and HFpEF during hospitalization, in which biomarker associations are more 330 
angiogenesis and inflammation related in HFpEF, cardiac stretch related in HFrEF and both cardiac 331 
stretch and inflammation related in HFmrEF.  332 
   333 
 334 
Limitations of the study 335 
This study is a retrospective post-hoc analysis, which is accompanied by a possible selection bias. 336 
Not all patients had complete biomarker data available at admission and after 24h, creating a 337 
potential selection bias. Also, despite the large number of biomarker available, the choice for 338 
biomarkers was restricted by limited sample availability. It also needs to be emphasized that this is 339 
a data driven approach and causality cannot be proven. Results of this study need to be validated in 340 
a different population. Additionally, some echocardiographic measurements were performed 6 341 
months prior to admission. This did not seem to influence biomarker levels in HFrEF; HFmrEF and 342 
HFpEF, however we could not correct for this in network analysis. Differences with regard to 343 
outcome prediction should only be interpreted in the context of pathophysiological differences 344 
between HFrEF, HFmrEF and HFpEF and not with respect to possible clinical utility (10). For the 345 
latter, the relatively low number of events confounds the results with regard to predictive value. 346 
This was especially true for other outcomes (e.g., 30-day mortality) in the PROTECT trial, for 347 
which the number of events was even lower than the outcome used, making useful statistics on 348 
these outcomes not possible. Confirmation of the differential predictive value found is needed in 349 
more inclusive independent trials with larger number of events and HFmrEF and HFpEF patients.  350 
Conclusions. 351 
Clinical characteristics and biomarker profiles of patients with HFmrEF are between patients with 352 
HFrEF and HFpEF, suggesting HFmrEF to be a heterogeneous group. Biomarker associations in 353 
HFpEF were mostly inflammation based, whilst being more cardiac stretch based in HFrEF. 354 
Biomarkers related to inflammation and cardiac remodeling had predictive value in HFmrEF and 355 
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HFpEF, but not in HFrEF. These data suggest that patients with HFmrEF are a mix of HFrEF and 356 
HFpEF patients. Distinguishing HFmrEF patients closer to HFrEF could have important therapeutic 357 
consequences for this group. 358 
 359 
Competency in medical knowledge 360 
Differences between AHF patients with HFmrEF, HFrEF and HFpEF have not been well 361 
characterized. Results from this study suggest that AHF patients with HFpEF have a significantly 362 
different biomarker profile from patients with HFrEF. Herein, we found that inflammation plays a 363 
larger role in patients with HFpEF compared to HFrEF. Secondly, patients with HFmrEF are in 364 
between patients with HFpEF and HFrEF. This suggests that these patients should be carefully 365 
considered when treating according to guidelines, since some of them might be closer to HFrEF and 366 
some might be closer to HFpEF. Lastly, a change in inflammation biomarker levels might hold 367 
prognostic value for patients with HFpEF and HFmrEF.  368 
 369 
Translational outlook. 370 
Biomarker based characterization of patient populations might help to identify novel treatment 371 
targets as well as decipher disease heterogeneity and underlying differences in pathophysiology. 372 
While biomarker based clinical studies can be considered a crude tool, it can be the first step in 373 
identifying novel disease entities and pathophysiological targets. Findings from biomarkers based 374 
studies, including this one, should be validated in an experimental setting. 375 
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Figure legends:  
Figure 1: Network analysis illustrating correlative associations between biomarkers for HFrEF at admission (a) and 24 hours (b). The size and color of 
each node (hub) depicts the clustering coefficient where a large node reflects a high clustering coefficient. In addition, a color closer to blue depicts a 
higher clustering coefficient, while a color closer to red is associated with a lower clustering coefficient. Furthermore, the thickness and color of the 
lines connecting biomarkers to each other reflect the strength of the inter-biomarker associations. 
Figure 2: Network analysis illustrating correlative associations between biomarkers for HFmrEF at admission (a) and 24 hours (b). The size and color 
of each node (hub) depicts the clustering coefficient where a large node reflects a high clustering coefficient. In addition, a color closer to blue depicts 
a higher clustering coefficient, while a color closer to red is associated with a lower clustering coefficient. Furthermore, the thickness and color of the 
lines connecting biomarkers to each other reflect the strength of the inter-biomarker associations. 
Figure 3: Network analysis illustrating correlative associations between biomarkers for HFpEF at admission (a) and 24 hours (b). The size and color of 
each node (hub) depicts the clustering coefficient where a large node reflects a high clustering coefficient. In addition, a color closer to blue depicts a 
higher clustering coefficient, while a color closer to red is associated with a lower clustering coefficient. Furthermore, the thickness and color of the 
lines connecting biomarkers to each other reflect the strength of the inter-biomarker associations. 
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Table 1: Biomarker classification 
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Angiogenin             X         
BNP       X               
BUN               X X     
Creatinine               X       
CRP X         X           
D-Dimer X                   X 
Endothelin-
1 
X   X X             X 
ESAM X         X X         
Galectin-3 X X           X       
GDF-15 X X X     X           
Hemoglobin                   X   
Interleukin-
6 
X                     
KIM-1               X       
LTBR X         X           
Mesothelin                     X 
MPO X   X                 
Neuropilin         X   X       X 
NGAL X             X       
NT-proCNP         X             
Osteopontin X X       X X         
PCT X                     
Pentraxin-3 X                     
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Periostin   X                 X 
PIGR X                   X 
Platelet 
count 
                  X X 
proADM         X             
PSAP-B     X               X 
RAGE X         X           
RBC count                       
ST-2 X X X X     X         
Syndecan-1 X X                   
TNF-R1a X                     
Troponin-I       X               
TROY X X                   
VEGFR             X         
WAP4C X                   X 
WBC count X                 X   
Abbreviations: CRP, C-reactive protein; ESAM, endothelial cell-selective adhesion molecule; ET-1, endothelin-1; GDF-15, growth differentiation factor 15; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart 
failure with a reduced ejection fraction; IL-6, interleukin-6; KIM-1, kidney injury molecule 1; LTBR, lymphotoxin beta receptor; NGAL, neutrophil Gelatinase-associated Lipocalin; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; NT-proCNP, N-terminal pro-C-type natriuretic peptide; PCT, procalcitonin; PIGR, Polymeric immunoglobulin receptor; proADM, pro-adrenomedulin; PSAP-B, Prosaposin B; RAGE, Receptor for advanced  glycation 
end product; RBC, red blood cell count; ST-2, Soluble ST-2; TNF-R1, tumor necrosis factor alpha receptor 1; VEGFR-1, vascular endothelial growth receptor 1A, WAP-4C, WAP Four-Disulphide Core Domain Protein HE; 
WBC, white blood cell count. 
 
Table 2: Baseline characteristics. 
  
HFrEF HFmrEF HFpEF 
p-
value 
p-
value 
trend 
N 607 128 108     
Demographics           
Age, years, mean ± SD 68.0 ± 12.0 70.7 ± 11.3 74.4 ± 10.1 <0.001 <0.001 
Female sex, n (%) 
137 
(22.6%) 76 (59.4%) 57 (52.8%) <0.001 <0.001 
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BMI, kg/m2, mean ± SD 28.1 ± 5.7 29.0 ± 7.1 29.6 ± 7.0 0.029 0.027 
eGFR, mL/min/1.73 m2, 
mean ± SD 48.4 ± 19.5 48.1 ± 18.7 47.0 ± 21.5 0.800 0.353 
NYHA class, n (%)       0.290 0.186 
   I/II 90 (15.6%) 27 (21.8%) 16 (16.5%) 
  
   III 
329 
(57.1%) 64 (51.6%) 61 (62.9%)   
 
   IV 
157 
(27.3%) 33 (26.6%) 20 (20.6%)   
 LVEF, median (IQR) 25 (20, 30) 42 (40, 45) 56 (50, 60) <0.001 <0.001 
Systolic BP, mmHg, mean 
± SD 
119.3 ± 
17.2 
127.1 ± 
16.0 
134.2 ± 
17.2 <0.001 <0.001 
Diastolic BP, mmHg, 
mean ± SD 72.5 ± 11.9 73.5 ± 12.2 74.7 ± 13.5 0.190 0.027 
Heart rate, b.p.m. mean ± 
SD 80.3 ± 14.9 78.5 ± 15.6 79.0 ± 16.8 0.410 0.588 
Rolofylline, n(%) 406(66.9%) 90 (70.3%) 70 (64.8) 0.648  0.920 
Medical history, n (%)           
Mitral regurgitation,  
298 
(49.2%) 40 (31.3%) 28 (26.2%) <0.001 <0.001 
Heart failure (HF),  
578 
(95.2%) 
124 
(96.9%) 97 (89.8%) 0.034 0.078 
Hospitalization for HF 
previous year 
356 
(58.6%) 70 (54.7%) 49 (45.4%) 0.034 0.011 
HF hospitalizations, 
median (IQR) 
1.0 (1.0, 
2.0) 
1.0 (1.0, 
2.0) 
1.0 (1.0, 
2.0) 0.560 0.278 
Ischemic heart disease 
434 
(71.7%) 86 (67.2%) 58 (53.7%) <0.001 <0.001 
Myocardial infarction 
351 
(58.0%) 57 (44.5%) 25 (23.4%) <0.001 <0.001 
Hypertension 
425 
(70.0%) 
112 
(87.5%) 95 (88.0%) <0.001 <0.001 
Stroke or PVD 
117 
(19.3%) 25 (19.5%) 24 (22.2%) 0.780 0.519 
COPD or asthma 
146 
(24.2%) 15 (11.7%) 26 (24.1%) 0.008 0.261 
Diabetes mellitus 
275 
(45.4%) 63 (49.2%) 42 (38.9%) 0.280 0.419 
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Atrial Fibrillation/Flutter 
305 
(50.5%) 69 (53.9%) 71 (65.7%) 0.014 0.005 
Medication prior to 
admission, n (%)           
Beta-blockers 
485 
(80.0%) 93 (72.7%) 85 (78.7%) 0.180 0.348 
ACE-I/ARB 
455 
(75.1%) 91 (71.1%) 82 (75.9%) 0.610 0.86 
MRA 
311 
(51.3%) 49 (38.3%) 32 (29.6%) <0.001 <0.001 
Digoxin 
170 
(28.1%) 35 (27.3%) 23 (21.3%) 0.350 0.182 
Nitrates 
142 
(23.5%) 28 (21.9%) 26 (24.1%) 0.910 0.984 
CCBs 41 (6.8%) 22 (17.2%) 28 (25.9%) <0.001 <0.001 
Presenting signs & 
symptoms, n (%)           
Orthopnea 
489 
(82.5%) 
105 
(83.3%) 85 (79.4%) 0.710 0.564 
Dyspnea at rest (NYHA 
IV) 
323 
(55.6%) 71 (57.7%) 56 (54.4%) 0.870 0.963 
Angina pectoris 
117 
(19.3%) 31 (24.2%) 21 (19.6%) 0.450 0.602 
Edema 
155 
(25.6%) 30 (23.4%) 34 (31.5%) 0.340 0.349 
JVP 
251 
(45.6%) 52 (46.8%) 39 (39.4%) 0.480 0.362 
 
Abbreviations: ACE-I, ACE-inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated 
glomerular filtration rate; HFpEF, heart failure with a preserved ejection fraction; HFmrEF, heart failure with a reduced ejection fraction; IQR, inter-quartile range; JVP, Increased jugular venous pressure; LVEF, left ventricular 
ejection fraction; MRA, mineral receptor antagonist; NYHA, New York heart association; PVD, peripheral vascular disease; SD, standard deviation 
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Table 3: Biomarker levels at admission. 
  
HFrEF HFmrEF HFpEF p-value 
p-
value* 
p-value for 
trend 
p-value for 
trend* 
N 607 128 108         
Inflammation/Immune 
system               
WBC (x109/L) 7.6 (6.2, 9.2) 7.3 (6.3, 8.8) 7.4 (6.1, 10.0) 0.560 1.000 0.997 1.000 
CRP (ng/ml) 
13350.1 (7116.7, 28145.4) 12937.1 (7483.5, 26490.9) 
18801.0 (10274.2, 
31983.5) 0.043 1.000 0.025 0.675 
GDF-15 (ng/ml) 4.9 (3.1, 6.3) 4.1 (2.9, 6.3) 4.5 (3.0, 6.3) 0.034 0.924 0.022 0.594 
PCT (ng/ml) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.820 1.000 0.603 1.000 
Pentraxin-3 (ng/ml) 4.5 (3.0, 7.0) 3.8 (2.5, 7.3) 3.9 (2.8, 6.3) 0.074 1.000 0.057 1.000 
RAGE (ng/ml) 5.1 (3.7, 6.8) 4.8 (3.5, 6.5) 4.7 (3.6, 6.6) 0.500 1.000 0.245 1.000 
TNF-R1a (ng/ml) 3.3 (2.2, 4.8) 3.0 (2.1, 4.6) 3.6 (2.3, 5.2) 0.120 1.000 0.325 1.000 
TROY (ng/ml) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.540 1.000 0.408 1.000 
Interleukin 6 (pg/ml) 11.0 (6.0, 21.2) 10.2 (6.2, 15.7) 13.3 (6.6, 22.3) 0.400 1.000 0.764 1.000 
Oxidative stress               
MPO (ng/ml) 32.7 (17.8, 67.1) 35.3 (16.1, 78.2) 32.3 (16.6, 66.7) 0.950 1.000 0.999 1.000 
Remodeling               
Syndecan-1 (ng/ml) 8.5 (7.2, 10.6) 8.1 (6.9, 9.7) 8.8 (7.1, 10.8) 0.093 1.000 0.442 1.000 
Periostin (ng/ml) 5.8 (3.4, 9.7) 5.7 (3.4, 8.8) 5.4 (3.1, 8.5) 0.440 1.000 0.198 1.000 
Galectin-3 (ng/ml) 36.2 (27.0, 48.5) 35.4 (27.3, 48.7) 40.1 (30.3, 53.1) 0.039 1.000 0.300 1.000 
Osteopontin (ng/ml) 112.1 (78.6, 172.4) 112.7 (84.2, 151.3) 112.9 (71.3, 179.9) 0.920 1.000 0.687 1.000 
ST-2 (ng/ml) 3.4 (1.0, 8.7) 2.8 (0.9, 6.6) 3.9 (1.2, 7.2) 0.150 1.000 0.565 1.000 
Cardiomyocyte 
stress/injury               
BNP (pg/ml) 520.9 (289.5, 877.9) 397.3 (214.8, 667.9) 300.1 (221.7, 600.9) <0.001 <0.001 <0.001 <0.001 
Troponin I (pg/ml) 11.9 (6.0, 23.6) 10.9 (6.1, 23.3) 8.4 (4.7, 18.5) 0.0515 1.000 0.026 0.702 
Angiogenesis/Endothelial 
function               
VEGFR (ng/ml) 0.4 (0.3, 0.6) 0.4 (0.2, 0.5) 0.3 (0.2, 0.5) 0.036 0.976 0.012 0.324 
Angiogenin (ng/ml) 1856.6 (1245.7, 2723.7) 2080.2 (1353.0, 2893.4) 1755.9 (1333.6, 2917.9) 0.160 1.000 0.639 1.000 
Neuropilin (ng/ml) 12.9 (8.3, 18.3) 11.2 (8.1, 15.4) 12.2 (8.1, 17.0) 0.170 1.000 0.184 1.000 
proADM (ng/ml) 2.9 (1.6, 5.0) 2.5 (1.5, 4.1) 2.8 (1.5, 5.3) 0.150 1.000 0.739 1.000 
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NTpro-CNP (ng/ml) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.750 1.000 0.451 1.000 
Atherosclerosis               
ESAM (ng/ml) 62.5 (56.4, 70.0) 61.7 (56.1, 68.3) 62.6 (57.5, 70.5) 0.440 1.000 0.872 1.000 
LTBR (ng/ml) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.5 (0.3, 0.6) 0.140 1.000 0.068 1.000 
Renal function               
NGAL (ng/ml) 81.9 (54.4, 129.5) 76.8 (55.7, 143.9) 102.0 (62.9, 154.9) 0.033 0.883 0.020 1.000 
KIM 1 (pg/ml) 269.4 (178.6, 462.9) 327.5 (218.2, 650.2) 351.2 (232.3, 585.7) 0.001 0.021 <0.001 <0.001 
BUN (mg/dl) 31.0 (23.0, 44.0) 28.0 (21.0, 39.0) 30.0 (22.0, 41.0) 0.060 1.000 0.135 1.000 
Hematopoiesis               
RBC (x1012/L) 4.2 (3.8, 4.7) 4.2 (3.7, 4.6) 3.9 (3.5, 4.4) <0.001 <0.001 <0.001 <0.001 
Hemoglobin (g/dL) 12.6 (11.4, 13.8) 12.1 (10.8, 13.6) 11.6 (10.4, 12.6) <0.001 <0.001 <0.001 <0.001 
Other               
Endothelin 1 (pg/ml) 6.9 (5.2, 9.3) 6.3 (4.8, 8.0) 6.3 (4.2, 9.2) 0.015 0.402 0.009 0.243 
D-Dimer (ng/ml) 155.2 (90.6, 340.3) 171.0 (90.6, 333.8) 176.0 (90.6, 338.6) 0.350 1.000 0.187 1.000 
PIGR (ng/ml) 406.0 (262.5, 647.1) 379.9 (274.9, 604.5) 401.3 (256.3, 694.4) 0.880 1.000 0.815 1.000 
PSAP-B (ng/ml) 40.6 (29.5, 55.2) 34.8 (26.6, 52.8) 36.3 (26.8, 56.7) 0.035 1.000 0.076 1.000 
WAP4C (ng/ml) 28.8 (14.9, 55.0) 28.2 (13.8, 49.5) 28.5 (14.4, 59.6) 0.720 1.000 0.978 1.000 
Mesothelin (ng/ml) 88.4 (75.2, 102.4) 85.4 (71.4, 96.6) 87.8 (77.4, 103.8) 0.097 1.000 0.443 1.000 
Glucose (mg/dL) 126.0 (103.0, 159.0) 119.0 (97.0, 166.0) 121.0 (94.0, 159.0) 0.310 1.000 0.128 1.000 
Platelet count (x109/L) 212.0 (165.0, 264.0) 215.0 (170.0, 287.0) 238.5 (190.0, 308.0) 0.010 0.279 0.003 0.081 
Abbreviations: CRP, C-reactive protein; ESAM, endothelial cell-selective adhesion molecule; ET-1, endothelin-1; GDF-15, growth differentiation factor 15; HFpEF, heart failure with a preserved ejection fraction; HFrEF, heart 
failure with a reduced ejection fraction; IL-6, interleukin-6; KIM-1, kidney injury molecule 1; LTBR, lymphotoxin beta receptor; NGAL, neutrophil Gelatinase-associated Lipocalin; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; NT-proCNP, N-terminal pro-C-type natriuretic peptide; PCT, procalcitonin; PIGR, Polymeric immunoglobulin receptor; proADM, pro-adrenomedulin; PSAP-B, Prosaposin B; RAGE, Receptor for advanced  glycation 
end product; RBC, red blood cell count; ST-2, Soluble ST-2; TNF-R1a, tumor necrosis factor alpha receptor 1; VEGFR-1, vascular endothelial growth receptor 1A, WAP-4C, WAP Four-Disulphide Core Domain Protein HE; 
WBC, white blood cell count. 
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